Clinical Trial Update: RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for RC48 (disitamab vedotin) in platinum-sensitive recurrent ovarian cancer expressing HER2; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• RC48 (disitamab vedotin)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 2 | Status: RECRUITING